A Multicenter, Phase 1-2 Study of MLN8237, an Oral Aurora A Kinase Inhibitor, in Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma Treated With Rituximab and Vincristine [Estudio multicéntrico en fase 1-2 de MLN8237, un inhibidor oral de la cinasa Aurora A, en pacientes con linfoma de células B agresivo recidivante o resistente tratados con rituximab y vincristina].

Trial Profile

A Multicenter, Phase 1-2 Study of MLN8237, an Oral Aurora A Kinase Inhibitor, in Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma Treated With Rituximab and Vincristine [Estudio multicéntrico en fase 1-2 de MLN8237, un inhibidor oral de la cinasa Aurora A, en pacientes con linfoma de células B agresivo recidivante o resistente tratados con rituximab y vincristina].

Completed
Phase of Trial: Phase I/II

Latest Information Update: 16 Nov 2016

At a glance

  • Drugs Alisertib (Primary) ; Rituximab; Vincristine
  • Indications Burkitt's lymphoma; Diffuse large B cell lymphoma; Follicular lymphoma; Mantle-cell lymphoma
  • Focus Adverse reactions; Pharmacogenomic; Therapeutic Use
  • Sponsors Takeda Oncology
  • Most Recent Events

    • 10 Nov 2016 Status changed from active, no longer recruiting to completed.
    • 08 Apr 2016 Planned End Date changed from 1 Dec 2015 to 1 Aug 2016 as reported by ClinicalTrials.gov.
    • 31 Mar 2015 Planned End Date changed from 1 Jun 2014 to 1 Dec 2015 as reported by ClinicalTrials.gov
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top